225 related articles for article (PubMed ID: 33758118)
1. Statewide Availability of Buprenorphine/Naloxone in Acute Care Hospitals.
Pham S; Haigh A; Barrett E
J Addict Med; 2022 Jan-Feb 01; 16(1):e48-e51. PubMed ID: 33758118
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
[TBL] [Abstract][Full Text] [Related]
3. Where Opioid Overdose Patients Live Far From Treatment: Geospatial Analysis of Underserved Populations in New York State.
Abell-Hart K; Rashidian S; Teng D; Rosenthal RN; Wang F
JMIR Public Health Surveill; 2022 Apr; 8(4):e32133. PubMed ID: 35412467
[TBL] [Abstract][Full Text] [Related]
4. Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.
Kazerouni NJ; Irwin AN; Levander XA; Geddes J; Johnston K; Gostanian CJ; Mayfield BS; Montgomery BT; Graalum DC; Hartung DM
Drug Alcohol Depend; 2021 Jul; 224():108729. PubMed ID: 33932744
[TBL] [Abstract][Full Text] [Related]
5. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
[TBL] [Abstract][Full Text] [Related]
6. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
[TBL] [Abstract][Full Text] [Related]
7. Simulating the Simultaneous Impact of Medication for Opioid Use Disorder and Naloxone on Opioid Overdose Death in Eight New York Counties.
Cerdá M; Hamilton AD; Hyder A; Rutherford C; Bobashev G; Epstein JM; Hatna E; Krawczyk N; El-Bassel N; Feaster DJ; Keyes KM
Epidemiology; 2024 May; 35(3):418-429. PubMed ID: 38372618
[TBL] [Abstract][Full Text] [Related]
8. Local health departments and the implementation of evidence-based policies to address opioid overdose mortality.
Feuerstein-Simon R; Lowenstein M; Sharma M; Dupuis R; Luna Marti X; Cannuscio CC
Subst Abus; 2020; 41(4):468-474. PubMed ID: 32213045
[TBL] [Abstract][Full Text] [Related]
9. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
[TBL] [Abstract][Full Text] [Related]
10. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
[TBL] [Abstract][Full Text] [Related]
11. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.
Shearer D; Young S; Fairbairn N; Brar R
Drug Alcohol Rev; 2022 Feb; 41(2):444-448. PubMed ID: 34647379
[TBL] [Abstract][Full Text] [Related]
12. Caring for patients with opioid use disorder in the hospital.
Donroe JH; Holt SR; Tetrault JM
CMAJ; 2016 Dec; 188(17-18):1232-1239. PubMed ID: 27647616
[No Abstract] [Full Text] [Related]
13. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
14. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
[TBL] [Abstract][Full Text] [Related]
15. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
[TBL] [Abstract][Full Text] [Related]
16. The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost?
Gregg J; Hartley J; Lawrence D; Risser A; Blazes C
J Addict Med; 2023 Jan-Feb 01; 17(1):7-9. PubMed ID: 35913990
[TBL] [Abstract][Full Text] [Related]
17. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
[No Abstract] [Full Text] [Related]
18. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
Saunders EC
Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
[No Abstract] [Full Text] [Related]
19. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island.
Zang X; Macmadu A; Krieger MS; Behrends CN; Green TC; Morgan JR; Murphy SM; Nolen S; Walley AY; Schackman BR; Marshall BD
Int J Drug Policy; 2021 Dec; 98():103435. PubMed ID: 34482264
[TBL] [Abstract][Full Text] [Related]
20. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method.
Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR
J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
